clinical trial · NCT05026866
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company·phase3·active not recruiting·n = 2,996
Alzheimer DiseaseDonanemabPlacebo
brief summary
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
started
Aug 27, 2021
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Jan 21, 2026
official title
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol